HUE051862T2 - Stabil, IFNAR1-elleni készítmény - Google Patents

Stabil, IFNAR1-elleni készítmény

Info

Publication number: HUE051862T2
Authority: HU; Hungary
Prior art keywords: ifnar1; preparation; stable anti; stable; ifnar1 preparation
Prior art date: 2015-08-19

Application number

HUE16837818A

Other languages

English (en)

Inventor

Roberto Depaz

Natalie Dejesus

Jared Bee

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-08-19

Filing date

2016-08-18

Publication date

2021-03-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58052002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE051862(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-08-18 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2021-03-29 Publication of HUE051862T2 publication Critical patent/HUE051862T2/hu

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Biophysics (AREA)
Mycology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Oil, Petroleum & Natural Gas (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)

HUE16837818A 2015-08-19 2016-08-18 Stabil, IFNAR1-elleni készítmény HUE051862T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201562207164P	2015-08-19	2015-08-19

Publications (1)

Publication Number	Publication Date
HUE051862T2 true HUE051862T2 (hu)	2021-03-29

Family

ID=58052002

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HUE20174805A HUE061985T2 (hu)	2015-08-19	2016-08-18	Stabil IFNAR1-elleni készítmény
HUE16837818A HUE051862T2 (hu)	2015-08-19	2016-08-18	Stabil, IFNAR1-elleni készítmény

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HUE20174805A HUE061985T2 (hu)	2015-08-19	2016-08-18	Stabil IFNAR1-elleni készítmény

Country Status (25)

Country	Link
US (1)	US10125195B2 (hu)
EP (3)	EP3337502B1 (hu)
JP (4)	JP6720293B2 (hu)
KR (4)	KR20240090616A (hu)
CN (1)	CN107921109A (hu)
AU (3)	AU2016308262C1 (hu)
BR (1)	BR112018002196A8 (hu)
CA (1)	CA2995222C (hu)
CY (2)	CY1123657T1 (hu)
DK (2)	DK3337502T3 (hu)
ES (2)	ES2818229T3 (hu)
FI (1)	FI3769781T3 (hu)
HK (1)	HK1256195A1 (hu)
HR (2)	HRP20230463T1 (hu)
HU (2)	HUE061985T2 (hu)
IL (1)	IL257279B2 (hu)
LT (2)	LT3337502T (hu)
PL (2)	PL3769781T3 (hu)
PT (2)	PT3337502T (hu)
RS (2)	RS60773B1 (hu)
RU (1)	RU2731737C2 (hu)
SG (1)	SG10202106970XA (hu)
SI (2)	SI3769781T1 (hu)
SM (2)	SMT202300176T1 (hu)
WO (1)	WO2017031288A1 (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10125195B2 (en)	2015-08-19	2018-11-13	Astrazeneca Ab	Stable anti-IFNAR1 formulation
GB201719447D0 (en)	2017-11-23	2018-01-10	Ucb Biopharma Sprl	Pharmaceutical composition
US20200061015A1 (en) *	2018-08-23	2020-02-27	Janssen Biotech, Inc.	Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
AU2020225202B2 (en)	2019-02-18	2023-10-26	Eli Lilly And Company	Therapeutic antibody formulation
CN110179746A (zh) *	2019-05-17	2019-08-30	通化东宝生物科技有限公司	一种稳定的苏金单抗注射剂及其制备方法
DK4058060T3 (da) *	2019-11-11	2025-03-17	Astrazeneca Ab	Type i-interferon-hæmning ved systemisk lupus erythematosus
CN115667309A (zh) *	2020-05-29	2023-01-31	阿斯利康(瑞典)有限公司	使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病
AU2021295605A1 (en)	2020-06-25	2023-02-16	Eli Lilly And Company	Prevention of axonal damage using antibody binding to amyloid BETA 1-42
TW202237647A (zh)	2020-10-08	2022-10-01	瑞典商阿斯特捷利康公司	狼瘡發作之治療
JP2024518735A (ja) *	2021-04-23	2024-05-02	アストラゼネカ・アクチエボラーグ	抗ｉ型ｉｎｆ受容体抗体アニフロルマブによるループス腎炎の治療
CA3216390A1 (en) *	2021-04-23	2022-10-27	Astrazeneca Ab	Treatment of cutaneous lupus erythematous
CN117157099A (zh) *	2021-04-23	2023-12-01	阿斯利康(瑞典)有限公司	用于皮下注射的抗ifnar1给药方案
CA3216387A1 (en)	2021-04-23	2022-10-27	Astrazeneca Ab	Anti-ifnar1 dosing regime for subcutaneous injection
WO2022238479A1 (en) *	2021-05-12	2022-11-17	Astrazeneca Ab	Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients
CN113527490B (zh) *	2021-07-13	2022-03-01	江苏荃信生物医药股份有限公司	一种抗人ifnar1单克隆抗体浓缩溶液的制备方法
WO2023284073A1 (zh) *	2021-07-13	2023-01-19	江苏荃信生物医药股份有限公司	降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂
CN113521276B (zh) *	2021-07-13	2022-04-12	江苏荃信生物医药股份有限公司	包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂
AU2022317215A1 (en)	2021-07-27	2024-02-29	Astrazeneca Ab	Treatment of lupus
AU2022359684A1 (en) *	2021-10-04	2024-05-09	Astrazeneca Ab	Treatment of lupus
EP4422674A1 (en) *	2021-10-29	2024-09-04	Intas Pharmaceuticals Ltd.	Stable lyophilized formulation of an anti-alpha 4beta7 antibody
TW202337497A (zh) *	2022-02-18	2023-10-01	中國大陸商重慶明道浩悅生物科技有限公司	鼻內調配物及抗sars-cov-2棘蛋白抗體
IN202221038828A (hu) *	2022-07-06	2024-01-12
WO2024079241A1 (en)	2022-10-13	2024-04-18	Astrazeneca Ab	Treatment of lupus
WO2024241156A1 (en)	2023-05-19	2024-11-28	Astrazeneca Ab	Treatment of lupus
WO2025022280A1 (en)	2023-07-21	2025-01-30	Astrazeneca Ab	Treatment of neurodegenerative diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US6713609B1 (en) *	1996-07-16	2004-03-30	Genentech, Inc.	Monoclonal antibodies to type I interferon receptor
CN101001878B (zh) *	2004-06-21	2012-09-26	米德列斯公司	干扰素α受体1抗体及其用途
JO3000B1 (ar) *	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
CN101553504A (zh)	2006-12-11	2009-10-07	豪夫迈·罗氏有限公司	Aβ抗体胃肠外制剂
CA2692165A1 (en)	2007-06-25	2008-12-31	Amgen Inc.	Compositions of specific binding agents to hepatocyte growth factor
JP5490714B2 (ja) *	2007-11-28	2014-05-14	メディミューン，エルエルシー	タンパク質製剤
KR101666229B1 (ko) *	2008-02-08	2016-10-14	메디뮨 엘엘씨	Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
BRPI0921845A2 (pt) *	2008-11-12	2019-09-17	Medimmune Llc	formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
US20110152188A1 (en) *	2009-12-23	2011-06-23	Hanns-Christian Mahler	Pharmaceutical compositions of igf/i proteins
US20110223208A1 (en) *	2010-03-09	2011-09-15	Beth Hill	Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
SG11201400815TA (en)	2011-10-12	2014-09-26	Ascendis Pharma Ophthalmology Division As	Prevention and treatment of ocular conditions
CN104023748B (zh) *	2011-10-28	2018-03-02	诚信生物公司	含有氨基酸的蛋白质制剂
US8883979B2 (en)	2012-08-31	2014-11-11	Bayer Healthcare Llc	Anti-prolactin receptor antibody formulations
US9592297B2 (en) *	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
RU2015119547A (ru) *	2012-10-25	2016-12-20	МЕДИММЬЮН, ЭлЭлСи	Стабильный низковязкий состав с антителом
AU2014265624B2 (en)	2013-05-15	2019-09-12	Medimmune Limited	Purification of recombinantly produced polypeptides
IL312865B1 (en) *	2013-09-11	2025-02-01	Eagle Biologics Inc	Liquid protein formulations containing viscosity-reducing agents
US20160250329A1 (en) *	2013-10-29	2016-09-01	Albumedix A/S	Antibody composition
AU2015310879A1 (en)	2014-09-03	2017-03-02	Medimmune Limited	Stable anti-IL-4R-alpha antibody formulation
WO2016109822A1 (en)	2014-12-31	2016-07-07	Novelmed Therapeutics, Inc.	Formulation of aglycosylated therapeutic antibodies
US10125195B2 (en)	2015-08-19	2018-11-13	Astrazeneca Ab	Stable anti-IFNAR1 formulation

2016
- 2016-08-18 US US15/240,224 patent/US10125195B2/en active Active
- 2016-08-18 LT LTEP16837818.0T patent/LT3337502T/lt unknown
- 2016-08-18 CA CA2995222A patent/CA2995222C/en active Active
- 2016-08-18 DK DK16837818.0T patent/DK3337502T3/da active
- 2016-08-18 SM SM20230176T patent/SMT202300176T1/it unknown
- 2016-08-18 AU AU2016308262A patent/AU2016308262C1/en active Active
- 2016-08-18 DK DK20174805.0T patent/DK3769781T5/da active
- 2016-08-18 SI SI201631699T patent/SI3769781T1/sl unknown
- 2016-08-18 BR BR112018002196A patent/BR112018002196A8/pt active Search and Examination
- 2016-08-18 SM SM20200483T patent/SMT202000483T1/it unknown
- 2016-08-18 PL PL20174805.0T patent/PL3769781T3/pl unknown
- 2016-08-18 SG SG10202106970XA patent/SG10202106970XA/en unknown
- 2016-08-18 EP EP16837818.0A patent/EP3337502B1/en active Active
- 2016-08-18 KR KR1020247016705A patent/KR20240090616A/ko active Pending
- 2016-08-18 IL IL257279A patent/IL257279B2/en unknown
- 2016-08-18 RS RS20201103A patent/RS60773B1/sr unknown
- 2016-08-18 RU RU2018107725A patent/RU2731737C2/ru active
- 2016-08-18 HR HRP20230463TT patent/HRP20230463T1/hr unknown
- 2016-08-18 HU HUE20174805A patent/HUE061985T2/hu unknown
- 2016-08-18 WO PCT/US2016/047506 patent/WO2017031288A1/en active Application Filing
- 2016-08-18 PT PT168378180T patent/PT3337502T/pt unknown
- 2016-08-18 RS RS20230447A patent/RS64263B1/sr unknown
- 2016-08-18 JP JP2018508149A patent/JP6720293B2/ja active Active
- 2016-08-18 PT PT201748050T patent/PT3769781T/pt unknown
- 2016-08-18 EP EP20174805.0A patent/EP3769781B1/en active Active
- 2016-08-18 PL PL16837818T patent/PL3337502T3/pl unknown
- 2016-08-18 ES ES16837818T patent/ES2818229T3/es active Active
- 2016-08-18 KR KR1020207029325A patent/KR102669174B1/ko active Active
- 2016-08-18 ES ES20174805T patent/ES2947488T3/es active Active
- 2016-08-18 FI FIEP20174805.0T patent/FI3769781T3/fi active
- 2016-08-18 CN CN201680047012.7A patent/CN107921109A/zh active Pending
- 2016-08-18 HU HUE16837818A patent/HUE051862T2/hu unknown
- 2016-08-18 SI SI201630900T patent/SI3337502T1/sl unknown
- 2016-08-18 EP EP23160045.3A patent/EP4233892A3/en active Pending
- 2016-08-18 KR KR1020187007314A patent/KR102168005B1/ko active Active
- 2016-08-18 KR KR1020227031079A patent/KR20220127378A/ko not_active Ceased
- 2016-08-18 LT LTEP20174805.0T patent/LT3769781T/lt unknown
2018
- 2018-11-29 HK HK18115287.0A patent/HK1256195A1/zh unknown
2020
- 2020-05-21 AU AU2020203306A patent/AU2020203306C1/en active Active
- 2020-06-17 JP JP2020104494A patent/JP7035119B2/ja active Active
- 2020-08-19 HR HRP20201297TT patent/HRP20201297T1/hr unknown
- 2020-09-11 CY CY20201100860T patent/CY1123657T1/el unknown
2021
- 2021-10-26 AU AU2021257915A patent/AU2021257915A1/en not_active Abandoned
2022
- 2022-03-02 JP JP2022031581A patent/JP2022066345A/ja active Pending
2023
- 2023-06-20 CY CY20231100289T patent/CY1126062T1/el unknown
2024
- 2024-08-22 JP JP2024140769A patent/JP2024161043A/ja active Pending

Also Published As

Publication number	Publication date
EP3769781A1 (en)	2021-01-27
HUE061985T2 (hu)	2023-09-28
CN107921109A (zh)	2018-04-17
AU2016308262B2 (en)	2020-04-30
AU2020203306C1 (en)	2022-03-31
IL257279A (en)	2018-03-29
EP4233892A2 (en)	2023-08-30
RS60773B1 (sr)	2020-10-30
AU2016308262A1 (en)	2018-03-08
SI3769781T1 (sl)	2023-06-30
KR20200119916A (ko)	2020-10-20
BR112018002196A2 (pt)	2019-04-30
SMT202000483T1 (it)	2020-11-10
EP3337502A1 (en)	2018-06-27
KR20180041173A (ko)	2018-04-23
DK3337502T3 (da)	2020-09-14
AU2020203306B2 (en)	2021-09-09
DK3769781T5 (da)	2024-08-19
AU2016308262C1 (en)	2022-04-21
JP2022066345A (ja)	2022-04-28
KR20240090616A (ko)	2024-06-21
CA2995222C (en)	2021-07-13
SMT202300176T1 (it)	2023-07-20
KR102669174B1 (ko)	2024-06-10
JP2020158527A (ja)	2020-10-01
JP7035119B2 (ja)	2022-03-14
RU2731737C2 (ru)	2020-09-08
AU2021257915A1 (en)	2021-11-18
RU2018107725A (ru)	2019-09-19
CA2995222A1 (en)	2017-02-23
BR112018002196A8 (pt)	2021-05-04
US20170051066A1 (en)	2017-02-23
DK3769781T3 (da)	2023-06-19
PT3769781T (pt)	2023-06-19
EP3337502A4 (en)	2019-01-23
HRP20230463T1 (hr)	2023-07-21
LT3337502T (lt)	2020-09-25
WO2017031288A1 (en)	2017-02-23
JP2018523676A (ja)	2018-08-23
ES2818229T3 (es)	2021-04-09
IL257279B2 (en)	2023-04-01
HRP20201297T1 (hr)	2020-11-27
US10125195B2 (en)	2018-11-13
JP2024161043A (ja)	2024-11-15
SG10202106970XA (en)	2021-07-29
RU2018107725A3 (hu)	2019-10-02
FI3769781T3 (fi)	2023-06-07
SI3337502T1 (sl)	2020-10-30
ES2947488T3 (es)	2023-08-10
CY1126062T1 (el)	2023-11-15
EP4233892A3 (en)	2023-10-25
KR20220127378A (ko)	2022-09-19
HK1256195A1 (zh)	2019-09-13
KR102168005B1 (ko)	2020-10-21
IL257279B (en)	2022-12-01
EP3769781B1 (en)	2023-04-19
LT3769781T (lt)	2023-06-12
JP6720293B2 (ja)	2020-07-08
PL3769781T3 (pl)	2023-07-17
EP3337502B1 (en)	2020-06-24
AU2020203306A1 (en)	2020-06-11
RS64263B1 (sr)	2023-07-31
CY1123657T1 (el)	2022-03-24
PL3337502T3 (pl)	2021-01-11
PT3337502T (pt)	2020-09-23

Publication	Publication Date	Title
HUE051862T2 (hu)	2021-03-29	Stabil, IFNAR1-elleni készítmény
IL255028A0 (en)	2017-12-31	Hydroponics
EP3374114A4 (en)	2019-04-10	WORKBENCH
HK1256839A1 (zh)	2019-10-04	臨床製劑
LT3230281T (lt)	2021-07-12	1,3-tiazol-2-ilu pakeisti benzamidai
FR3034146B1 (fr)	2017-09-01	Mousqueton
DK4032440T3 (da)	2023-09-04	Låganordning
HUE062754T2 (hu)	2023-12-28	Antimikrobiális készítmény
EP3366108A4 (en)	2019-06-19	MOWER
DK3442586T3 (da)	2022-09-12	Stabil parenteral nimopidinformulering
DK3253762T3 (da)	2021-07-19	9h-pyrrolo-dipyridinderivater.
BR112017001922A2 (pt)	2018-07-17	composições fungicidas
EP3364945C0 (en)	2024-12-04	SOLID FORMULATION
BR112017014838A2 (pt)	2018-06-19	benzoxaboróis microbicidas
ES1150114Y (es)	2016-04-25	Abarcón.
LT3253749T (lt)	2022-02-25	Junginiai, pasižymintys priešnavikiniu aktyvumu
PT3170887T (pt)	2019-06-04	Fermentador melhorado
DK3057373T3 (da)	2022-01-10	Enkeltcelle-punkt-til-multipunkt-overførsel
HUE047581T2 (hu)	2020-05-28	Készítmény
IL264442B (en)	2021-07-29	Antimicrobial composition
DE102015206660A8 (de)	2016-12-08	Plattenaufteilanlage
HUE066130T2 (hu)	2024-07-28	Duddingtonia flagranst tartalmazó készítmény
DK3464140T3 (da)	2021-10-04	Stakklargøringsenhed
IT201600069848A1 (it)	2018-01-05	Friggitrice.
DE112016001834A5 (de)	2018-01-11	Kanüle